Table 4.

Administration characteristics of currently approved GLP-1 RA prefilled pen devices

Generic name (commercial)	Exenatide twice daily (Byetta©)	Liraglutide (Victoza©)	Lixisenatide (Lyxumia©/Adlyxin©)	Exenatide QW (Bydureon©)	Dulaglutide (Trulicity©)	Semaglutide (Ozempic©)
Is reconstitution required?	No	No	No	Yes	No	No
Is dose administration automatic?	No	No	No	Yesa	Yes	No
Does the device need to be primed?	Yes	Yes	Yes	No	No	Yes
Does a needle need to be attached?	Yes	Yes	Yes	No	No	Yes
Is dose selection required?	Yes	Yes	No	No	No	Yes
Is the device for single use?	No	No	No	Yes	Yes	No

^aThe current device that delivers exenatide once weekly is the Bydureon BCise© pen (AstraZeneca plc, Cambridge, UK) that automatically administers the dose. Previous versions of the pen device do not automatically deliver the dose